Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › dinutuximab

dinutuximab

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of dinutuximab

9 trials tracked of dinutuximab: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 1834 citations.

9Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 4 Phase 1 2
  1. Phase 3 Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Completed · 1,834 cited
  2. Phase 3 Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer Completed · 48 cited
  3. Phase 3 Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma Completed
  4. Phase 2 Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Completed
  5. Phase 2 A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma Completed
  6. Phase 2 Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma Completed
Show 3 more trials
  1. Phase 2 Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Completed
  2. Phase 1 Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma Completed
  3. Phase 1 MIBG With Dinutuximab +/- Vorinostat Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Insufficient evidence exists to determine the independent clinical contribution of GM-CSF to anti-GD2 immunotherapy
Oncology Meta-analysis
Insufficient evidence exists to determine the independent clinical contribution of GM-CSF to anti-GD2 immunotherapy Evidence Lacks Clarity on GM-CSF Impact for Neuroblastoma Treatment
This systematic review evaluates the efficacy and safety of anti-GD2 immunotherapy with and without GM-CSF in patients with neuroblastoma. T…
Current research cannot determine if adding GM-CSF improves the effectiveness or safety of anti-GD2 immunotherapy for patients with neurobla…
Frontiers Sep 8, 2026